SEBI Reg. Investment Advisor

Download App

Help Center Subscribe

Recent:

Log In Sign Up Schedule Free 15‑min Call

Top Pharma Companies in India by Market Cap

BSE Sensex 78285.07
521.16 (0.67%)

Filter

Top Pharma Companies in India as on Jul-2026 | 5 Star Rated Stocks Undervalued Stocks Fair Valued Stocks Uptrend Stocks

Filter

	Company Name	DeciZen	Market cap (Rs. Cr.)	CMP (Change %)	Latest P/E	Latest P/BV	5Y Sales Gr.(%)	5Y Profit Gr.(%)
121	Acutaas Chemicals Ltd.	Q V+ PT	28,772 Small Cap	3,514.30 (-4.78%)	78.57	17.25	32.80	16.82	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
122	Indegene Ltd.	Q V+ PT	11,907 Small Cap	494.25 (-2.86%)	29.68	3.79	34.59	31.10	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
123	Max Healthcare Institute Ltd.	Q V+ PT	1,10,230 Mid Cap	1,132.60 (-1.78%)	76.42	10.25	46.01	60.18	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
124	3B Blackbio Dx Ltd.	Q V PT	1,034 Small Cap	1,205.20 (2.79%)	20.97	3.79	46.29	132.12	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
125	Fischer Medical Ventures Ltd.	Q V PT	2,479 Small Cap	37.87 (-3.66%)	N/A	7.94	96.10	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
126	Health X Platform Ltd.	Q V PT	1,018 Small Cap	320 (2.89%)	N/A	3.76	109.54	-201.92	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
Prev 1 2 3 4 5 Next

Screens:

AlphaCases Top Rated Stocks Best Nifty Stocks Best Nifty Next Stocks Best Nifty 500 Stocks Best SmallCap Stocks Top BFSI Stocks

Pharma - Today's Top Gainers

Company Name	CMP	Price Change(%)
Fermenta Biotech	395	14.21%
Tarsons Products	293.10	10.42%
Sun Pharma Adv. Res	261.65	9.41%
Artemis MedicareServ	276.30	6.11%
Rubicon Research	1,362.85	4.61%

Pharma - Today's Top Losers

Company Name	CMP	Price Change(%)
Supriya Lifescience	865.75	-11.62%
Acutaas Chemicals	3,514.30	-4.78%
Gufic Biosciences	375.05	-4.08%
Suven Life Sciences	314.90	-3.86%
Fischer Medical	37.87	-3.66%

News about Top Pharma Companies in India

23

Jun, 2026

Acutaas Chemicals informs about disclosures

Pursuant to the provisions of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and further to intimation dated June 22, 2026, Acutaas Chemicals has informed that the Central Goods & Service Tax & Central Excise (CGST & CE), Anti -evasion Department, Surat, Guijarat have concluded their Inspection/Search on June 23, 2026. The details required to be disclosed under the Listing Regulations read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/1/3762/2026 dated January 30, 2026 are enclosed to this letter as Annexure A.

The above information is a part of company’s filings submitted to BSE.

20

Jun, 2026

Max Healthcare Institute informs about AGM & record date

Max Healthcare Institute has informed about the following with respect to Annual General Meeting, Record Date and Communication sent to members for deduction of tax at source on final dividend: 1) Annual General Meeting: The Twenty-Fifth Annual General Meeting (‘AGM’) of members of the Company is scheduled to be held on Thursday, July 30, 2026 through video conference / other audio-visual means, in accordance with the applicable circulars issued by the Ministry of Corporate Affairs and the Securities and Exchange Board of India (‘SEBI’). 2) Record Date: Pursuant to Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Company has fixed Friday, July 3, 2026, as the ‘Record Date’ for determining the members entitled to receive the final dividend for the financial year 2025-26, if approved by members at the ensuing 25th AGM. 3) Communication to member for deduction of tax at source on final dividend: The Company has today, June 19, 2026, sent a detailed communication to all members of the Company, whose e-mail addresses are registered with the Company/ depositories, indicating the process and documentation required for claiming exemption from deduction of tax at source on final dividend for the financial year 2025-26, which is subject to the approval of members at the ensuing 25th AGM. A copy of e-mail communication sent to members is enclosed as Annexure. This disclosure will also be hosted on Company's website: www.maxhealthcare.in.

The above information is a part of company’s filings submitted to BSE.

19

Jun, 2026

Health X Platform informs about earnings call transcript

In furtherance to letter dated June 2, 2026 intimating that a Group Conference Call with investors and analysts was scheduled to be held on 12th June, 2026 at 4.00 PM (IST) to discuss the performance for the quarter and year ended March 31, 2026 and updates of the Company. Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Health X Platform has informed that it enclosed a copy of the transcript of the said call with the Investors and analysts. The link of the transcript of the said call has been uploaded on the website of the Company. http://healthxplatform.com/Pdf/HXPL_Q4_FY26_Earnings_Group_Conference_Call_Transcript.pdf

The above information is a part of company’s filings submitted to BSE.

06

Jun, 2026

Health X Platform informs about disclosure

Health X Platform has informed that it enclosed disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Ravi Kant Sharma & PACs.

The above information is a part of company’s filings submitted to BSE.

04

Jun, 2026

Indegene informs about analyst meet

Pursuant to the provisions of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, Indegene has informed that officials of the Company will be meeting Investors / Analysts as on 03 June 2026.

The above information is a part of company’s filings submitted to BSE.

02

Jun, 2026

Health X Platform submits intimation for change of website of company

With reference to earlier intimation dated 25th April, 2026 regarding the approval from Stock Exchanges for change in name of the Company in their records from Sastasundar Ventures Limited to Health X Platform Limited and in pursuance of the provisions of Regulation 30, 46 and other applicable regulations, if any, of the SEBI (LODR) Regulations, 2015, Health X Platform has informed that the website of the Company has been changed from https://www.sastasundarventures.com to https://www.healthxplatform.com with immediate effect.

The above information is a part of company’s filings submitted to BSE.

Publicly traded pharmaceuticals

Top 10 Publicly Listed pharmaceutical stocks in India by Market Capitalization as of 2026.

Rank	Company	Market Capitalization 2026 (INR crores)
1	Jubilant Pharmova Ltd.	15,703 Crore
2	Suven Life Sciences Ltd.	8,313 Crore
3	Aster DM Quality Care Ltd.	40,960 Crore
4	Panacea Biotec Ltd.	3,280 Crore
5	Sanofi India Ltd.	7,938 Crore
6	Nectar Lifesciences Ltd.	225 Crore
7	Novartis India Ltd.	3,602 Crore
8	Aurobindo Pharma Ltd.	91,709 Crore
9	Apollo Hospitals Enterprise Ltd.	1,27,858 Crore
10	Sun Pharma Advanced Research Company Ltd.	8,491 Crore

Do you know? Asking 3 Right Questions minimizes the RISK of Stock Investing To Know

Right Stock | Right Price | Right Allocation

Find best stocks to buy now Find best pharma stocks to buy now

Top 15 Pharma Stocks by Revenue Growth

Top Pharma Companies Source: NSE Indices

You can use different criterias to arrive at the list of best stocks in the Nifty Pharma company index. You can use return ratios like ROCE or ROE, that will help you choose companies with profitable growth.

Based on ROE, the best stocks in the Nifty Pharma companies index are:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	ROE
Abbott India Ltd. (M)	Very Good	26,852	57,058	36.76	11.95	25.14	35.71
Torrent Pharmaceuticals Ltd. (L)	Very Good	4,823	1,63,246	75.46	19.46	39.62	29.04
Ajanta Pharma Ltd. (M)	Very Good	3,371	42,118	39.88	9.31	26.95	25.35
Lupin Ltd. (M)	Somewhat Good	2,492	1,13,963	21.37	5.08	12.36	20.83
Zydus Lifesciences Ltd. (M)	Very Good	1,148	1,14,518	22.72	4.40	13.90	20.74

Based on the past year's gain, the best performing stocks are:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	Yearly gain (%)
Laurus Labs Ltd. (M)	Very Good	1,529	82,615	97.06
JB Chemicals & Pharmaceuticals Ltd. (S)	Very Good	2,391	38,385	46.04
Torrent Pharmaceuticals Ltd. (L)	Very Good	4,823	1,63,246	43.21
Aurobindo Pharma Ltd. (M)	Very Good	1,594	91,709	33.87
Gland Pharma Ltd. (S)	Very Good	2,462	40,621	31.41
				View More

Stocks with the highest revenue growth in the past 5 years is:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	5Y Sales Growth (%)
JB Chemicals & Pharmaceuticals Ltd. (S)	Very Good	2,391	38,385	56.94	9.51	34.49	15.51
Mankind Pharma Ltd. (M)	Very Good	2,540	1,04,911	51.49	6.40	32.31	14.65
Ajanta Pharma Ltd. (M)	Very Good	3,371	42,118	39.88	9.31	26.95	13.54
Dr. Reddys Laboratories Ltd. (M)	Very Good	1,369	1,14,246	27.23	3.03	15.19	12.09
Torrent Pharmaceuticals Ltd. (L)	Very Good	4,823	1,63,246	75.46	19.46	39.62	11.80

Stocks with high profit growth often witness their stock prices gaining, irrespective of the market movements.

Stocks with the highest profit growth in the past 5 years is:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	5Y Profit Growth (%)
Zydus Lifesciences Ltd. (M)	Very Good	1,148	1,14,518	22.72	4.40	13.90	30.57
Sun Pharmaceutical Industries Ltd. (L)	Very Good	1,913	4,59,005	39.98	5.49	22.91	23.50
Abbott India Ltd. (M)	Very Good	26,852	57,058	36.76	11.95	25.14	18.78
Dr. Reddys Laboratories Ltd. (M)	Very Good	1,369	1,14,246	27.23	3.03	15.19	15.75
Glenmark Pharmaceuticals Ltd. (M)	Very Good	2,270	64,072	47.05	6.10	12.50	14.41

You have 9 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login | Register Now

Create stable, long-term investment portfolio with strong, consistent stocks.

Start Research-backed Investing ...Now. Subscribe to Sapphire

2026 ©The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me® is a registered trademark of The Alchemists Ark Pvt. Ltd.

About MoneyWorks4Me

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Fiduciary-first advisory model.
As SEBI-registered IAs, we are legally and ethically bound to act in the best interests of our clients. We do not sell or distribute any financial products. This ensures our guidance is 100% unbiased and conflict-free.
Deep fundamental research + robust valuation discipline.
Built on more than 15 years of equity research, our framework combines quality assessment, intrinsic value estimation, and a sensible margin-of-safety approach.
Process—not predictions.
We don’t rely on guesswork or market timing. Instead, we focus on asset allocation, risk management, and long-term compounding.
Technology + Human Intelligence.
We believe a combination of both is essential for investing success. We constantly innovate and upgrade in-house tools, financial X-rays, and portfolio analytics so that our team of analysts and advisors are equipped with the best.
Partner with Clients.
We follow a DIWM (Do-It-With-Me) approach where we partner clients in setting goals, financial planning, educating on our investing process and share decision-enabling resources transparently with our clients who retain control on execution.

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

Investing in stocks, mutual funds, debt, and gold
Quality-at-Reasonable-Price way of investing in stocks
Constructing Direct Stock Portfolios with Core, Booster, and Amplifier stocks
A Mutual Fund Portfolio that delivers consistent out-performance and meaningful diversification (low overlap)
Periodic review and rebalancing
Clear Buy-Sell-Hold, and Position-sizing frameworks